

---

# Contents

---

Preface.....	vii
Series Editor Preface.....	ix
<b>1 Pathophysiology of Type-2 Diabetes.....</b>	<b>1</b>
Etiology.....	1
Natural History of Type-2 Diabetes.....	2
Pathophysiology.....	4
The Natural History of Type-2 Diabetes.....	5
Summary.....	12
References.....	12
Supplementary Readings.....	13
<b>2 Guidelines and Classifications.....</b>	<b>15</b>
Classes of Diabetes.....	15
Type-1 Diabetes (Insulin Dependent Diabetes).....	15
Type-2 Diabetes (Non-Insulin Dependent Diabetes).....	16
Diabetes Associated with Other Risk Factors.....	20
Diagnosing Diabetes.....	23
Screening Recommendations.....	24
Efficacy of Diets and Medications.....	27
Gestational Diabetes.....	28
Malnutrition Associated Diabetes.....	29
References.....	30
Supplementary Readings.....	31
<b>3 Exercise.....</b>	<b>33</b>
Introduction.....	33
Guidelines for Exercise.....	37
Precautions.....	38
Effects and Timing of Exercise.....	38
Stress Testing.....	38
Types of Stress Tests.....	40
Summary.....	45
References.....	45
Supplementary Readings.....	46
<b>4 Nutrition.....</b>	<b>47</b>
Introduction.....	47
Diabetes and Carbohydrates.....	48
Diabetes and Protein.....	52

Diabetes and Fats .....	53
References.....	63
Supplementary Readings.....	65
<b>5 Obesity and the Metabolic Syndrome .....</b>	<b>67</b>
Introduction.....	67
The Metabolic Syndrome.....	68
Obesity .....	79
Summary .....	89
References.....	89
Supplementary Readings.....	92
<b>6 Oral Agents for Type-2 Diabetes .....</b>	<b>93</b>
Introduction.....	93
Oral Agent Classes.....	97
Sulfonylureas.....	97
The Meglitinides (Glinides) .....	99
The Biguanides.....	100
The Alpha-Glucosidase Inhibitors .....	102
The Thiazolidinediones.....	103
DPP-IV Inhibitors (Gliptins).....	107
Bile Acid Sequestrants (Colesevelam).....	110
Oral Agent Combinations .....	111
Metformin and Sulfonylurea.....	111
Metformin and Thiazolidinediones .....	112
Metformin and Repaglinide .....	112
Metformin and Nateglinide.....	112
Repaglinide and Thiazolidinedione.....	113
Sulfonylurea and Thiazolidinedione .....	113
Alpha-Glucosidase Inhibitors and Sulfonylurea .....	113
DDP-IV Inhibitors and Metformin and/or Thiazolidinediones.....	114
Combinations with Bile Acid Sequestrants.....	114
Multiple Oral Agent Therapy.....	114
Summary .....	119
References.....	119
Supplementary Readings.....	122
<b>7 Insulin Use .....</b>	<b>123</b>
Introduction.....	123
Indications for Insulin Therapy .....	126
Human Insulin Preparations.....	129
Insulin Analogs .....	130
Intermediate-Acting Insulins.....	136
Pre-Mixed (Biphasic) Insulins .....	136
Multiple Daily Injections .....	138
Continuous Subcutaneous Insulin Infusion Pumps.....	141
General Therapeutic Principles .....	142
Novel Therapies .....	143
Summary .....	145
Case 1 .....	146

Case 2.....	146
Case 3.....	147
Case 4.....	147
Case 5.....	148
References.....	149
Supplementary Readings.....	151
<b>8 Non-Insulin Injectables .....</b>	<b>153</b>
Introduction.....	153
GLP-1 Receptor Agonists (Incretin Mimetics).....	156
Exenatide (Byetta) (Exendin-4) .....	156
Liraglutide (Victoza).....	160
Pramlintide (Symlin).....	162
Summary .....	167
References.....	167
<b>9 Macrovascular Disease .....</b>	<b>169</b>
Introduction.....	169
Coronary Artery Disease.....	169
Peripheral Arterial Disease .....	177
Cerebral Arteriosclerotic Vascular Disease.....	182
Summary .....	184
References.....	184
Supplementary Readings.....	186
<b>10 Microvascular Disease .....</b>	<b>187</b>
Introduction.....	187
Diabetic Neuropathy .....	192
Diabetic Nephropathy .....	201
Pathophysiology of Diabetic Nephropathy .....	202
Summary .....	209
References.....	209
Supplementary Readings.....	211
<b>11 Diabetic Dyslipidemia.....</b>	<b>213</b>
Introduction.....	213
Pathogenesis of Diabetic Dyslipidemia .....	213
Risk Assessment .....	216
Clinical Impact of Diabetic Dyslipidemia.....	218
Dyslipidemia Therapy in the Diabetic Patient .....	220
Statins-HMG-CoA Inhibitors (3-Hydroxy-3 Methylglutaryl-Coenzyme	
A Reductase Inhibitors).....	220
Niacin (Nicotinic Acid).....	221
Bile Acid Sequestrants .....	221
Fibrates Selective Cholesterol Absorption Inhibitors .....	222
Omega-3 Acid Ethyl Esters (Fish Oils) (Omega-3 Fatty Acids).....	223
Summary .....	235
References.....	235
Supplementary Readings.....	237

<b>12 Hypertension in Diabetics .....</b>	<b>239</b>
Introduction.....	239
Classification of Hypertension.....	240
Pathophysiology of Hypertension in Obesity and Type-2 Diabetes .....	240
Treatment for the Hypertensive Type-2 Diabetic.....	244
The Role of Combination Therapy .....	253
Summary .....	262
References.....	262
Supplementary Readings.....	264
<b>13 The Pathophysiology and Metabolic Impact of Hyperglycemia.....</b>	<b>267</b>
Introduction.....	267
Pathophysiology of Hyperglycemia.....	268
Clinical Impact of Hyperglycemia.....	270
Summary .....	278
References.....	278
Supplementary Readings.....	279
<b>14 Risk Reduction in the Diabetic Patient .....</b>	<b>281</b>
Introduction.....	281
Glycemic Control.....	282
Lipid Control.....	289
Primary Prevention.....	289
Secondary Prevention.....	290
Hypertension .....	297
Thrombosis Prevention .....	302
Multiple Risk Factor Reduction .....	305
Summary .....	310
References.....	310
Supplementary Readings.....	314
<b>15 Diabetes in Special Populations .....</b>	<b>317</b>
Mental Health and Type-2 Diabetes.....	317
Type II Diabetes in Children .....	320
Diabetes in Women .....	321
Background.....	321
Prevention of Type-2 Diabetes.....	323
Gestational Diabetes.....	323
Screening for Coronary Heart Disease.....	326
Other Complications of Diabetes in Women.....	327
Infections.....	327
Gynecological Abnormalities.....	327
Risk Reduction in the Female Diabetic Patient.....	328
Summary .....	335
The Geriatric Patient .....	335
Type-2 Diabetes and Acquired Immune Deficiency Syndrome (AIDS).....	339
Type-2 Diabetes and Hemodialysis.....	340
Foot Problems in the Diabetic Patient.....	342
Perioperative and Postoperative Glucose Control.....	343
Skin Disorders in Type-2 Diabetes .....	344

---

Resources .....	346
References .....	349
Supplementary Readings.....	353
Index .....	357



<http://www.springer.com/978-1-60327-440-1>

Type 2 Diabetes, Pre-Diabetes, and the Metabolic Syndrome

Codario, R.A.

2011, XV, 367 p., Hardcover

ISBN: 978-1-60327-440-1

A product of Humana Press